Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

'We're ready': Schiphol airport gears up for chilled vaccine cargos

Thu, 26th Nov 2020 13:29

* Air France-KLM has already shipped vaccines at -80C

* Schiphol is Europe's second largest pharmaceutical hub

* Air France-KLM adding extra cold storage at Schiphol

By Toby Sterling

SCHIPHOL AIRPORT, Netherlands, Nov 26 (Reuters) - In
cavernous cold-storage warehouses at Amsterdam's Schiphol
Airport, KLM workers are gearing up for a surge next year in
COVID-19 vaccine cargos that will need to be flown around the
world at ultra-low temperatures.

A major hub for pharmaceutical products, Schiphol has
already handled some of the vaccines being used in trials and
KLM's boss is confident its "cold chain" operations will cope
with the influx of cargos as mass inoculations start in earnest.

"The short and sweet of it is, yes, we're ready," KLM Chief
Executive Pieter Elbers told Reuters. "Obviously both for
societies and our industry it's of paramount importance to have
these vaccines distributed at the quickest possible pace."

While no COVID-19 vaccine has yet been approved by U.S. or
European regulators, the shot developed by Pfizer and
BioNTech is the most advanced in the process and could
be ready for rapid production and distribution next month.

But it needs to be stored and shipped at minus 70 degrees
Celsius while Moderna's candidate has to be kept at
-20C, at least until the drugs have reached their destinations
where they can survive in normal fridges for short periods.

Allowed behind strict security at Schiphol on Wednesday,
Reuters watched Air France-KLM staff prepare four
so-called active containers for a shipment of chilled
pharmaceuticals bound for Toronto in Canada.

Wearing thick blue gloves, workers topped up dry ice in
other active containers, which also have a battery-powered
electrical refrigeration system and an array of sensors to
ensure products stay within their target range, as low as -20C.

"Schiphol will, for sure, be one of the major airports for
the vaccines," said Marcel Kuijn, global head of pharmaceutical
logistics for Air France-KLM Cargo.

"Our market share on the routes we fly is 10% to 20%, that's
in our regular pharma business, so we expect to get at least
that part of the vaccine distribution," he told Reuters.

COOL BOXES

Pfizer's vaccine is transported at -80C in small cool boxes
holding about 5,000 doses which must be kept packed in dry ice
until shortly before use. Moderna's candidate is suitable for
the larger "active" containers which can take 30,000 doses.

The vaccine being developed by AstraZeneca and
Oxford University is stable at normal fridge temperatures of 2C
to 8C so it has more transport options.

Kuijn estimated that while vaccines will begin and end their
journeys in refrigerated trucks, at least 30% will be flown to
their destinations.

Schiphol is the second biggest hub for pharmaceutical
products in Europe after Frankfurt so it is expected to be both
a staging ground for vaccines from India, Italy or the United
States, and a departure point for vaccines made in Europe.

Some other vaccines being developed in China are also stable
in normal fridges and Kuijn reckons only a minority COVID-19
shots will need to be transported frozen.

Air France-KLM currently operates 537 flights a week to
about 100 destination in Asia, the Middle East, Africa and the
Americas. It is likely that Franco-Dutch airline will be a major
carrier to African countries, given its network.

Kuijn said bottlenecks at Schiphol were unlikely, and while
containers would be in high demand, he did not expect shortages
as different vaccines will come available at different times.

"The first ones will probably come in December, January, and
from there on new vaccines will be approved," he said.

The KLM Cargo warehouse at Schiphol has four cold storage
areas for pharmaceuticals and a fifth will be ready in January.

"The bigger containers can carry up to 30,000 doses of the
vaccine," said Paul Crombach, program manager of KLM's "cool
chain" programme and the head of the team preparing for the mass
transport of COVID-19 vaccines.

"We knew we're going to have to transport a lot of the
vaccine ... but we have space as you can see," he said,
gesturing to the vast warehouse behind him decked out with
conveyor belts and robotic lifting arms.
(Reporting by Toby Sterling; Editing by David Clarke)

More News
19 Jun 2023 06:55

LONDON MARKET EARLY CALL: Stocks to fall but pound rises ahead of BoE

(Alliance News) - Stocks in London are set to open lower on Monday, with a Bank of England decision ahead, and as developments in US-China relations are also in focus.

Read more
16 Jun 2023 12:59

Sell GBP on aggressive BoE pricing - Danske Bank

STOXX 600 up 0.6%

*

Read more
15 Jun 2023 17:02

LONDON MARKET CLOSE: Europe mixed after ECB hike and hawkish Fed

(Alliance News) - London's FTSE 100 closed higher, though equities in mainland Europe weakened, after both the Federal Reserve and European Central Bank both hinted that they are not done with rate hikes.

Read more
13 Jun 2023 08:41

AstraZeneca wins approval in China for Soliris in myasthenia gravis

(Alliance News) - AstraZeneca PLC on Tuesday announced another approval in China for Soliris to treat a rare neuromuscular disease.

Read more
12 Jun 2023 13:08

Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease

June 12 (Reuters) - Novartis said it has agreed to acquire U.S. biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment.

Read more
12 Jun 2023 08:39

AstraZeneca breast cancer drug capivasertib gets priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its breast cancer drug capivasertib in combination with breast-cancer treating hormone therapy drug faslodex has been granted priority review in the US for patients with advanced HR-positive breast cancer.

Read more
9 Jun 2023 10:09

AstraZeneca gets new FDA RSV approval, partners with Quell

(Sharecast News) - AstraZeneca announced on Friday that the US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) had unanimously voted in favour of 'nirsevimab' as a preventive treatment for respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants.

Read more
9 Jun 2023 09:11

TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data

(Alliance News) - AstraZeneca PLC on Friday reported positive phase 3 trial data for its oral drug danicopan and struck an agreement with London-based biopharma company Quell Therapeutics Ltd.

Read more
9 Jun 2023 07:55

LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout

(Alliance News) - Stocks in London were called to open higher on Friday, after a weak US jobless claims reading threw "cold water" over expectations for an interest rate hike by the Federal Reserve next week.

Read more
9 Jun 2023 06:53

AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee

(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab.

Read more
5 Jun 2023 17:17

London stocks slip as global growth concerns weigh

Indivior jumps on U.S. Suboxone lawsuit settlement

*

Read more
5 Jun 2023 16:59

AstraZeneca and Daiichi Sankyo report progress in cancer drug trials

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday reported positive results from trials of two cancer drugs, Enhertu and datopotamab deruxtecan.

Read more
5 Jun 2023 09:48

AstraZeneca stops Andexxa trial early, Tagrisso reduces death risk

(Alliance News) - AstraZeneca PLC on Monday said its Andexxa phase four trial will be stopped early after achieving positive efficacy data.

Read more
2 Jun 2023 18:04

AstraZeneca sees positive results for Imfinzi in gastric cancers

(Alliance News) - AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers.

Read more
1 Jun 2023 08:07

TOP NEWS: AstraZeneca discontinues brazikumab; Lynparza wins approval

(Alliance News) - AstraZeneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn's disease-focused brazikumab.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.